Travel

Categories, unlike tags, can have a hierarchy.

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary
Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”),…

Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial
Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial 2560 1707 Diffusion Pharmaceuticals Inc.

Twenty-four patient Phase 1b safety and tolerability study initiated in Romania CHARLOTTESVILLE, Va., Sept. 10,…

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”),…

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors
Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors 2560 1707 Diffusion Pharmaceuticals Inc.

Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial CHARLOTTESVILLE, Va., Sept. 01,…

Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

Continues global clinical development of TSC for the treatment of COVID-19 CHARLOTTESVILLE, Va., Aug. 10,…

Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC 2560 1707 Diffusion Pharmaceuticals Inc.

Guidance being incorporated into global study protocol Enrollment of first patient now expected in August…

Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc
Diffusion Pharmaceuticals Files Ind for International Phase 1b/2b COVID-19 Clinical Program With Tsc 2560 1707 Diffusion Pharmaceuticals Inc.

Phase 1b dosing expected to begin this month Data read-out expected later this quarter CHARLOTTESVILLE,…

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients
Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected…

  • 1
  • 2
Back to top